Table 1.
Baseline characteristics for the mild and moderate AD study population
| Baseline Characteristics | Mild AD study population |
Moderate AD study population |
||||
|---|---|---|---|---|---|---|
| Placebo (n = 663)∗ | Solanezumab (n = 659)∗ | Total (N = 1322) | Placebo (n = 359)∗ | Solanezumab (n = 364)∗ | Total (N = 723) | |
| Age, mean (SD), years | 73.3 (7.9) | 73.9 (8.1) | 73.6 (8.0) | 73.7 (8.2) | 73.9 (8.2) | 73.8 (8.1) |
| Female, n (%) | 362 (54.6) | 346 (52.5) | 708 (53.6) | 210 (58.5) | 234 (64.3) | 444 (61.4) |
| APOE4 carriers, n (%)† | 367 (59.8) | 329 (55.3) | 696 (57.6) | 201 (61.8) | 199 (61.0) | 400 (61.4) |
| SOC medication at baseline, n (%) | 587 (88.5) | 574 (87.1) | 1161 (87.8) | 333 (92.8) | 337 (92.6) | 670 (92.7) |
| Baseline efficacy measures | ||||||
| MMSE | 22.5 (2.8) | 22.5 (2.8) | 22.5 (2.8) | 17.8 (2.5) | 17.9 (2.6) | 17.8 (2.6) |
| ADAS-Cog14 | 29.6 (8.8) | 30.1 (8.6) | 29.9 (8.7) | 42.6 (10.8) | 42.1 (9.6) | 42.3 (10.2) |
| ADCS-iADL | 42.9 (9.5) | 42.4 (10.0) | 42.7 (9.7) | 34.4 (11.3) | 34.8 (10.8) | 34.6 (11.0) |
Abbreviations: ADAS-Cog, Alzheimer's Disease Assessment Scale—Cognitive subscale (14 item); ADCS-iADL, Alzheimer's Disease Cooperative Study Instrumental Activities of Daily Living Inventory; MMSE, mini mental state examination; SOC, standard of care.
∗
Number of randomized subjects. For baseline efficacy measures, the number of subjects included in each analysis varies based on the number of subjects with a baseline value for that measure.
†
Percentage based on number of subjects with APOE4 status available (mild placebo, 614; mild solanezumab, 595; moderate placebo, 325; and moderate solanezumab, 326).